Beneficial effects of tripterygium glycosides tablet on biomarkers in patients with ankylosing spondylitis

Molecular Medicine Reports
Wei JiYanna Song

Abstract

The aim of the current study was to explore the effects and possible mechanisms of tripterygium glycosides tablet (TGT) in the treatment of active ankylosing spondylitis (AS). Thirty-six patients with active AS were given a 20 mg TGT treatment three times per day for 12 weeks, and 21 unrelated healthy controls were recruited as the control group. Efficacy measures included the Bath AS disease activity index (BASDAI), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) prior and subsequent to TGT treatment. Serum dickkopf homolog 1 (DKK1) and interleukin-17 (IL-17) levels before and after TGT treatment were assessed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and ELISA assay. The levels of several serum biomarkers were determined by ELISA, including receptor activator of nuclear factor κ-B ligand (RANKL), osteoprotegerin (OPG), bone alkaline phosphatase (BAP), bone morphogenetic protein-2 (BMP-2), matrix metalloproteinase-3 (MMP-3), cross-linked telopeptide of type II collagen (CTX-II), vascular endothelial growth factor (VEGF), and prostaglandin E2 (PGE2). After 12 weeks of TGT treatment, the BASDAI score of the patients was significantly reduced (P<0.05), their levels of ESR and C...Continue Reading

References

Jul 4, 2002·Wiener medizinische Wochenschrift·C GoldbergerM Schirmer
Mar 14, 2007·Seminars in Arthritis and Rheumatism·Swee Cheng NgJieruo Gu
Mar 21, 2007·Joint, Bone, Spine : Revue Du Rhumatisme·Daniel WendlingGilles Dumoulin
Apr 24, 2007·Lancet·Jürgen Braun, Joachim Sieper
Feb 2, 2008·Arthritis Research & Therapy·Qing Yu ZengNai Zheng Zhang
Feb 3, 2009·Arthritis Research & Therapy·Walter P Maksymowych
Dec 30, 2009·Arthritis and Rheumatism·Dimitrios DaoussisAndrew P Andonopoulos
Apr 30, 2010·Science Translational Medicine·Steven MinearJill A Helms
Dec 17, 2010·Clinical Rheumatology·Yang MeiDongqing Ye
Mar 25, 2011·The American Journal of the Medical Sciences·John D Reveille
Jun 15, 2011·Best Practice & Research. Clinical Rheumatology·Jane Zochling, Emma U R Smith
Feb 1, 2013·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Anishka S RolleSam H Poon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Angelman Syndrome

Angelman syndrome is a neurogenetic imprinting disorder caused by loss of the maternally inherited UBE3A gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Here is the latest research.